Abstract 2036
Background
As the worldwide prevalence of colorectal cancer (CRC) is increasing, it is of vital importance to reduce its morbidity and mortality by early detection. Saliva is a noninvasively accessible fluid that potentially reflects both oral and systemic diseases. We report here the investigation and validation of salivary biomarkers to distinguish patients with CRC from those with polyps and healthy controls.
Methods
Saliva samples from subjects with CRC, polyps, and healthy controls were collected after 9 hours of fasting, and were split into training and validation data. Capillary electrophoresis-mass spectrometry-based metabolomics was used to quantify numerous hydrophilic metabolites.
Results
A total of 2,602 unstimulated saliva samples were collected from 231 subjects with CRC, 99 subjects with polyps, and 2272 subjects with healthy controls. The data were randomly divided into training (n = 1,301) and validation data (n = 1301). Biomarkers for distinguishing subjects with CRC from the others, as well as metabolites that normalize whole saliva concentration were identified. Analysis of these metabolites using machine learning-based artificial intelligence showed a high area under the receiver operating characteristic curve (AUC = 0.876; P < 0.0001) in the training dataset. This combination also showed high AUC values using the validation dataset (AUC = 0.861; P < 0.0001). Saliva samples were also collected multiple times from identical subjects and the robustness of these biomarkers were confirmed.
Conclusions
Combinations of salivary metabolites show high potential as a screening tool for CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hiroshi Kuwabara.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract